Marine-Derived Natural Products with Potential Benefits on Human and Animal Health: Tackling Pathogenic Virus, Protozoal and MDR-Bacteria

A special issue of Marine Drugs (ISSN 1660-3397).

Deadline for manuscript submissions: closed (31 March 2023) | Viewed by 2688

Special Issue Editors

E-Mail Website
Guest Editor
Center for Marine Science, University of North Carolina at Wilmington, Wilmington, NC, USA
Interests: organic chemistry; marine natural products; solid-phase peptide synthesis; medicinal chemistry; isolation; structure elucidation; drug delivery; bioactive compounds

E-Mail Website
Guest Editor
Department of Chemistry, Federal University of Santa Catarina, Florianópolis 88040-900, Brazil
Interests: natural products chemistry and infectious diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Marine-derived organisms continue to attract attention as a rich source of structurally novel bioactive metabolites that are potential lead compounds for the development of new drugs. More than 99% of naturally occurring organisms remain unexplored because of the surge in marine biodiversity. This biodiversity changes according to many factors such as weather, ecosystem, human influence and non-identified species. The enumerated factors make the marine ecosystem an important niche of biologically relevant natural products. Therefore, it can contribute significantly to the discovery of novel metabolites with potent biological activities against pathogenic virus, protozoal and MDR bacteria.

This Special Issue within the Marine-Derived Natural Products Chemistry Section of Marine Drugs aims to collect original research and review articles regarding new culture techniques to produce marine microorganism-derived natural products, new natural products from other marine organisms, structure identification and biological activity against pathogenic virus, protozoals (plasmodium sp., Leishmaniasis sp., Trypanosoma sp. and others) and MDR bacteria.

The issue will also accept manuscripts that consider the total synthesis of marine-derived natural products and semisynthetic derivatives of marine natural products with the abovementioned biological activity and the mechanism of action.

We look forward to receiving your contributions.

Dr. Alain Simplice Leutou
Prof. Dr. Louis Pergaud Sandjo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Marine Drugs is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • marine natural products
  • structure elucidation
  • extraction and purification
  • biological activity
  • NMR and LC/MS
  • bioactive compounds
  • multidrug resistance
  • drug discovery

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


18 pages, 2721 KiB  
Polyphenolic Compounds Isolated from Marine Algae Attenuate the Replication of SARS-CoV-2 in the Host Cell through a Multi-Target Approach of 3CLpro and PLpro
by D. P. Nagahawatta, N. M. Liyanage, Jun-Geon Je, H. H. A. C. K. Jayawardhana, Thilina U. Jayawardena, Seong-Hun Jeong, Hyung-Jun Kwon, Cheol Soo Choi and You-Jin Jeon
Mar. Drugs 2022, 20(12), 786; - 19 Dec 2022
Cited by 10 | Viewed by 2235
A global health concern has emerged as a response to the recent SARS-CoV-2 pandemic. The identification and inhibition of drug targets of SARS-CoV-2 is a decisive obligation of scientists. In addition to the cell entry mechanism, SARS-CoV-2 expresses a complicated replication mechanism that [...] Read more.
A global health concern has emerged as a response to the recent SARS-CoV-2 pandemic. The identification and inhibition of drug targets of SARS-CoV-2 is a decisive obligation of scientists. In addition to the cell entry mechanism, SARS-CoV-2 expresses a complicated replication mechanism that provides excellent drug targets. Papain-like protease (PLpro) and 3-chymotrypsin-like protease (3CLpro) play a vital role in polyprotein processing, producing functional non-structural proteins essential for viral replication and survival in the host cell. Moreover, PLpro is employed by SARS-CoV-2 for reversing host immune responses. Therefore, if some particular compound has the potential to interfere with the proteolytic activities of 3CLpro and PLpro of SARS-CoV-2, it may be effective as a treatment or prophylaxis for COVID-19, reducing viral load, and reinstating innate immune responses. Thus, the present study aims to inhibit SARS-CoV-2 through 3CLpro and PLpro using marine natural products isolated from marine algae that contain numerous beneficial biological activities. Molecular docking analysis was utilized in the present study for the initial screening of selected natural products depending on their 3CLpro and PLpro structures. Based on this approach, Ishophloroglucin A (IPA), Dieckol, Eckmaxol, and Diphlorethohydroxycarmalol (DPHC) were isolated and used to perform in vitro evaluations. IPA presented remarkable inhibitory activity against interesting drug targets. Moreover, Dieckol, Eckmaxol, and DPHC also expressed significant potential as inhibitors. Finally, the results of the present study confirm the potential of IPA, Dieckol, Eckmaxol, and DPHC as inhibitors of SARS-CoV-2. To the best of our knowledge, this is the first study that assesses the use of marine natural products as a multifactorial approach against 3CLpro and PLpro of SARS-CoV-2. Full article
Show Figures

Figure 1

Back to TopTop